<DOC>
	<DOC>NCT00546260</DOC>
	<brief_summary>Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)</brief_summary>
	<brief_title>Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI</brief_title>
	<detailed_description>Patients with STEMI who are to undergo primary PCI will be randomized to an intravenous (iv) bolus of placebo vs. PRT060128 prior to angiography.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Persistent ST elevation ≥ 1mm (≥ 0.1mV) in two contiguous limb leads OR ≥ 2 mm (≥ 0.2mV) in two contiguous precordial leads, AND chest pain ≥ 20 minutes with onset within 6 hours of hospital presentation. Cardiogenic shock (systolic blood pressure &lt; 90 mm Hg requiring vasopressor or hemodynamic support) Uncontrolled hypertension defined as any measured systolic blood pressure (SBP) &gt; 180 mm Hg or diastolic blood pressure (DBP) ≥ 110 mm Hg after the time History or symptoms of a congenital or acquired bleeding disorder or vascular malformation. Recent gastrointestinal bleeding within the last 30 days. Known thrombocytopenia (platelet count &lt; 100,000/mm3). Any treatment with a fibrinolytic agent within the last 7 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>STEMI</keyword>
	<keyword>ACS</keyword>
</DOC>